Regeneron, Parabilis Form $2.3B ADC-like Pact
May 18, 2026
Regeneron will pay Parabilis up to $2.3 billion to develop antibody-Helicon conjugates aimed at hard-to-drug intracellular targets.
First Gene Therapy Approved for Hearing Loss
April 23, 2026
FDA approved Regeneron's Otarmeni, first gene therapy for OTOF congenital deafness, via accelerated path using Commissioner's Priority Voucher.
Regeneron Enters Radiopharma via $2.1B Telix Deal
April 13, 2026
Regeneron expands into radiopharmaceuticals via $2.1B biobucks deal with Telix Pharmaceuticals to pair its biologics with Telix's lead-212-based alpha therapies.
Eylea Biosimilar Gains UK/EEA Launch Dates
January 30, 2026
ADVANZ and Alvotech settle Eylea patents with Bayer/Regeneron, enabling UK launch Jan 1 2026 and EEA/Switzerland May 1 2026.